drugset
drugset / Trial / NCT04684121

Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing

NCT04684121 ↗

Phase 2 Withdrawn Xequel Bio, Inc. United States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of Granexin® gel to promote accelerated healing of second-degree (deep partial thickness) thermal burns.

Timeline

Start
2022-08-01
Primary completion
2024-08-01
Completion
2024-08-01

Outcome

Outcome not reported

Stopped (Business): “No longer aligned with company strategy”

Drugs

EvaluationDrugModalityDoseRoute
Subject ACT-1 PEPTIDE Peptide 200 unknown Topical

Indications

No indication recorded.